Half Year Results
Record revenue of £32.5m driven by strong US growth
Adjusted EBITDA of £7.8m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited results for the six months ended 30 June 2024. All figures relate to this period unless otherwise stated.
Download
The full results are available to
download in PDF format
Strategic and post-period end highlights
- Significant progress in key US market, which has grown over two years to approximately 70% of total Annual Recurring Revenues
- Delivering behavioural health care in California, accessible to the State’s population of 13-25 year-olds, with sign-ups in every one of California’s 58 counties following service launch in January 2024
- First US private sector partnership with Aetna Better Health® of Illinois to support youth in low-income families
- Continued service delivery in Pennsylvania, with 88% of students reporting they received the support they needed and an initial tranche of new funding recently awarded
- Ongoing investment in product development highlighted by Soluna platform expansion with new video coaching and care navigation capabilities
- Maintained position as NHS England’s largest single access provider for mental health support for under 18s despite ongoing macro-economic conditions and broader NHS backdrop
Financial Highlights
- Revenues up 179% to £32.5m (2023: £11.7m), driven by US expansion
- Annual Recurring Revenue (ARR) up 181% to £60.0m (2023: £21.4m)
- Gross margin up 15.6ppt to 82.4% (2023: 66.8%)
- Adjusted EBITDA to £7.8m (2023: £0.0m)
- Profit after tax of £3.9m (2023: £0.5m loss)
- Robust balance sheet; net cash of £14.9m (2023: £5.9m) supports investment for long-term growth
Outlook
- US market:
- Significant opportunity driven by the continued need from both State Governments and private-sector healthcare service providers to invest further in youth mental health services
- Further two pilot contracts expected to be signed in the current financial year
- UK market:
- The new Government has highlighted its commitment to improving mental health services and invest more in prevention and digital, however headwinds remain with NHS financial pressures driving short-term focus
- Kooth to continue demonstrating the long-term impact and savings that it generates where it is commissioned and focus on advocacy to help inform future policy
- Investing in bringing Soluna to the UK in Q2 2025 to grow impact and expand uptake
- The Group expects to deliver strong adjusted EBITDA and margin for the full year
- Robust balance sheet to enable long-term investment to meet increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
“We have delivered excellent financial results in the first six months of 2024 but, more importantly, we have significantly expanded our operations and are now delivering our services to more children and young people than ever before. This growth has been led primarily by the US market, which now accounts for approximately 70% of our business.
In the UK we continue to demonstrate the long-term impact and savings that Kooth delivers where it is commissioned and are working to bring our market-leading Soluna product to the UK in Q2 2025 to ensure that we continue to differentiate Kooth and grow our reach and impact. We believe that the new Government is committed to improving mental health provision, and eagerly await the revised 10-year NHS strategy due in spring as a catalyst for change, but expect financial pressures to remain in the short-term.
As a Company we are focused on delivering early-intervention mental health support for children and young people which has proven to offer significant financial benefit to global healthcare systems and economies, both through our own studies and those carried out by third parties. Mental health and health inequality are two of the major crises facing people today, and we are proud that our services are firmly targeted at meeting both of these challenges.”
Financial headlines
| Six months ended 30 June 2024 | Six months ended 30 June 2023 | Change | |||
| £'000 | £'000 | ||||
| Revenue | |||||
| Total revenue | 32,494 | 11,660 | +178.7% | ||
| Annual Recurring Revenue | 60,040 | 21,376 | +180.9% | ||
| Gross profit | 26,767 | 7,788 | +243.7% | ||
| Gross margin | 82.4% | 66.8% | +15.6ppt | ||
| Adjusted EBITDA | 7,841 | 9 | n/m | ||
| Profit/(Loss) after tax for the period | 3,920 | (525) | +846.6% | ||
| Cash generation | 3,936 | (2,642) | +249.0% | ||
| Cash position | 14,940 | 5,850 | +155.4% | ||
| Basic earnings per share (£) | 0.11 | (0.02) | +775.5% | ||
| Diluted earnings per share (£) | 0.10 | (0.02) | +740.9% |
Chair’s Statement
Without doubt, 2023 has been a transformational year for Kooth, with significant growth and progress towards our vision to build mentally healthier populations by providing everyone with access to effective digital support from their first moment of need. I want to thank all members of the team in both the UK and US for their incredible hard work in delivering on the opportunities that have presented themselves to us. In addition, I want to record my appreciation to our customers who entrust us as custodians for the mental health of their populations.
Reflecting on the progress we have made in the US since late 2021 - first in Pennsylvania, and then in California - we are grateful for the endorsement of our innovation, clinical efficacy, and scale. The rapid progress we are making in the US would not be possible without the proof points we have developed over decades in the UK.
As a result of our $188m expected value, four-year contract win in California, we upgraded our growth outlook, and I am pleased to report 2023 Group revenues of £33.3 million, a 66% increase over 2022 revenues of £20.1 million, and over 40% increase in EBITDA to £2.3 million.
Given our rapid progress in California in particular, we successfully raised £10m of equity in July, primarily to invest in accelerating our US growth. I'm pleased to report that this has enabled us to expand our Sales and Research efforts, with discussions underway in a number of States, and a partnership with Aetna to pilot Kooth in Illinois to support youth in low-income families that qualify for Medicaid. The latter represents a potentially significant expansion of our modes of funding, and in turn a reinforcement of our market position.
Turning to the UK, 2023 has been a challenging year given the short-term financial and political pressures to reduce spending to pre-pandemic levels, whilst tackling the elective care waiting lists. Given the estimated £7 billion budget deficit at the start of 2023, NHS commissioners have been faced with difficult decisions to scale back services to balance budgets. As a result, churn in the UK has increased to £2.3m, up from £2.0m in 2022, with Kooth Adult pilot contracts being disproportionately impacted.
However, given the unsustainable, continued double-digit increase in demand for mental healthcare, and the political imperative to transform services for the benefit of society, NHS productivity, and the economy, we anticipate an improvement in the UK following the general election as NHS priorities and funding solidify.
Despite these short-term headwinds, Kooth's recurring revenue business model, with 98% of Kooth's contracts having a duration of 12 months or more, gives us strong forward revenue visibility, ending 2023 with £64.6m Annual Recurring Revenue (ARR), up from £21.1m a year ago.
We enter 2024 with significant growth opportunities, a solid financial position - £11.0m in cash, no debt, and an undrawn $9.5m working capital credit facility - a proven business model, and a strong social purpose.
Peter Whiting
Non-Executive Chair
25 March 2024
Chief Executive’s Review
Strong US momentum and expansion
We have delivered record results across our financial metrics during the first half of 2024, with revenue increasing 179% and ARR by 181% when compared to 2023. We have also seen significant momentum for Kooth in the US, highlighted by the successful launch of Soluna on 1 January in California, a key foundational pillar in the state's masterplan to transform youth mental healthcare. When combined with our robust balance sheet, we are well placed to continue investing in our services to improve the mental health of the population and deliver health economic outcomes to save healthcare systems money.
The benefit of this investment can be seen in Soluna, which is already making an impact with young people from all 58 counties in California, with 53% of users coming from communities disproportionately affected by health and economic inequities. The significant uptake among young people impacted by inequality underscores the importance of our role in addressing health inequities in the US. We continue to see encouraging data which demonstrate the benefits of the platform. For example, among those engaging with mental health coaches, 70% report positive outcomes from single-session therapy, and 95% would recommend Soluna to a friend.
Since launching Soluna we have also enhanced its capabilities. In the first half of the year, we introduced video-based 1-2-1 coaching to complement existing chat and phone options. We also launched care navigation support, making Soluna a digital front door for mental healthcare and welfare services across California. This allows us to quickly connect young people needing more acute or specialised care with appropriate local services. Looking ahead, we anticipate that these advancements will not only help establish Soluna as a strategic platform for transforming mental healthcare in California, but also serve as a strong foundation for broader US and UK expansion.
We continued to make progress in the US with our first private sector engagement, an initial one-year Medicaid partnership with Aetna Better Health® of Illinois. Medicaid – the state- and federally-funded insurance programme for low-income families – represents a $30.1 billion annual cost1 for youth behavioural health, with around 40 million children and young people across the US covered by Medicaid. Partnering with Medicaid providers like Aetna offers a differentiated route to market for Kooth and gives us the opportunity to deliver our services directly to millions of children and young people who may otherwise not be covered by State-led programmes. Given the growing demand and cost of behavioural healthcare, our partnership with Aetna aims to provide early intervention support to young people, reducing the need for more intensive and expensive downstream care. The service in Illinois launched in August, with our ambition to demonstrate our initial impact in Chicago before expanding across the state and potentially into the 15 other states where Aetna Better Health® operates.
Finally, in Pennsylvania, we continue to provide support to the student population as we finalise our commercial agreements with the state. While we saw a successful pilot of the service with one-in-ten of the eligible population using Kooth in its first year, the complexities of negotiating bipartisan agreements in the state have been a key learning for us as we look to future contracts elsewhere. Post-period end, an extended contract covering a period till mid-2025 has been agreed with the Department of Human Services, supported by an initial tranche of funding. Kooth is continuing to negotiate with relevant parties within Pennsylvania to finalise the total contract award and will update the market in due course.
Navigating the UK market
We have been pleased to see the positive indications from the new Government on the critical importance of improving access and investing in preventative mental health services, however the systemic challenges within the NHS, and the number of competing priorities faced in the short-term, suggest that substantial change will likely take some time. To ensure that our voice continues to be heard, we have bolstered our advocacy efforts as a champion and pioneer in digital mental health. For example, in June we hosted our first UK-US knowledge exchange event, bringing together stakeholders from California's mental health ecosystem with UK policy influencers and third-sector leaders. The events focused on the shared ambition and learnings in building a healthcare ecosystem focused on prevention, designing services 'with and for' young people, and improving access. We also intend to demonstrate our commitment to innovation by launching Soluna in the UK, expected in Q2 2025, which we believe will help grow usage and impact of the service.
More broadly, our strategic focus has been on delivering value and impact within our existing contracts and demonstrating the clinical benefits and cost-effectiveness of early digital intervention. We believe that if Kooth can continue to demonstrate its potential to have a positive impact on both youth mental health and healthcare system savings, we will play a crucial role in the future of the NHS.
Current trading and outlook
Looking ahead, our focus remains on driving innovation and scaling our technology platform and organisation to meet the growing demand for our services. In the US, we see significant opportunities as State Governments and Medicaid payors continue to invest in improving youth mental health provision. Given this investment, and recognition of the severe unmet need, we are optimistic about expanding our presence and demonstrating the value of Kooth's solutions in additional markets. This is supported by a strong pipeline of new business in the US, where we anticipate two new pilot contracts being signed later this year.
In the UK, our commitment to delivering impactful mental health support and advocating for digital transformation remains our key priority. We will continue to invest in our technology, systems and talent to support this mission, leveraging our experience and success in the US to inform and advocate for transformative change.
We remain confident in our ability to deliver strong results for the full year. Kooth is well-positioned to address the global challenge of youth mental health, and we will continue to focus on scaling our impact, enhancing our services and fulfilling our mission to provide accessible mental health support to those who need it most.
Tim Barker
Chief Executive
1 https://www.chcs.org/resource/faces-medicaid-childrens-behavioral-health-care-utilization-costs
Chief Financial Officer’s review
Kooth delivered a strong performance in the period, supported by record increases across revenue and annual recurring revenue, a strong gross margin as well as significant investment in our platform and the business for the half year ended 30 June 2024 as compared to the six months ended 30 June 2023.
Key Performance Indicators
Total Revenue
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| £5.9m | £8.0m | £9.0m | £11.7m | £32.5m |
Revenue is a KPI which reflects the work we are doing and the fees received over a period of time for that work. It has been driven by US growth, fee uplifts within ‘Children and Young People’ offset by churn in our UK revenue lines.
Annual Recurring Revenue
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| £13.1m | £16.6m | £18.5m | £21.4m | £60.0m |
Annual Recurring Revenue (ARR) is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long-term revenue growth of the business. Our growth in the period is predominantly driven by US expansion in California.
Gross Margin
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| 69.6% | 69.4% | 68.4% | 66.8% | 82.4% |
Gross margin is gross profit expressed as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services. We have seen an increase in gross margin driven by the US with the roll out of the Soluna app where we are initially seeing lower practitioner costs as contract usage ramps up and a greater use of the community and self guided tools. Gross margin has further benefitted from California revenues including a contribution to platform development, the cost of which is either included in overheads or capitalised and amortised.
Adjusted EBITDA
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| £0.5m | £1.1m | £0.5m | £0.0m | £7.8m |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group’s core business performance by removing the impact of non-trading items that are reported separately. Growth has been driven by revenue from our California contract and a strong gross margin.
Net Cash
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| £0.6m | £8.8m | £8.3m | £5.9m | £14.9m |
Net Cash is a key metric as it provides assurance on our ability to invest to grow the business, as well as provide comfort to customers from a vendor risk perspective. The increase in the period derives from working capital management as well as cash generated from operations offset by investment in our platforms.
Population coverage
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| 5.9m | 9.5m | 15.1m | 16.7m | 19.9m |
The total number of people who have access to the Kooth service is a good indicator of our accessibility. The H1 2024 figure represents the additional population added in California less churn within our UK adult contracts.
Service user logins
| H1 2020 | H1 2021 | H1 2022 | H1 2023 | H1 2024 |
| 1.0m | 1.2m | 1.4m | 1.4m | 1.4m |
The number of logins to Kooth from users over the last twelve months (LTM), demonstrating usage of our service.
Revenue
Revenue increased by 179% to £32.5m (2023 H1: £11.7m), Annual Recurring Revenue (ARR) grew by 181% to £60.0m (2023 H1: £21.4m), driven by the California contract win in H2 2023.
US Revenue in H1 2024 was £23.3m (2023 H1: £1.8m) all of which was recurring revenue (comprising income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract).
UK revenue decreased by 6% to £9.2m (2023 H1: £9.8m) reflecting an increase in churn in our English contracts being a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and a single competitive loss. Overall, UK churn for the previous 12 months was 13% (£2.4m) giving net revenue retention, measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients, for the period to 30 June 2024 of 92%. This has decreased from 100% recorded in H1 2023.
Gross Profit
Gross Profit increased 244% from £7.8m to £26.8m, with gross margin increasing to 82.4% (2023 H1: 66.8%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 303 at the period-end (2023 H1: 251 heads). Gross margin benefitted from the contribution within US revenues to the development of the Soluna platform where costs are either capitalised and amortised or included in overheads as well as lower practitioner costs as contract usage ramps up and a greater use of the community and self guided tools in the platform. We also saw productivity improvements and the churn of lower margin contracts in the UK leading to a small increase in UK gross margins.
Foreign currency impact
The US Dollar/GBP exchange rate was relatively stable during the period under review during which the Group had approximately 72% of revenues and 47% of expenses denominated in US Dollars. The Group’s focus on management of foreign currency risk resulted in a small foreign currency gain of £0.1m (2023 H1: nil). Post period end we have seen sterling strengthen against the US dollar which is expected to impact revenue in the second half. This is not anticipated to have a significant influence on margin or profitability.
Adjusted EBITDA
Adjusted EBITDA in the period increased from £0.0m to £7.8m, with the £19.0m increase in gross profit outweighing a £11.2m increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation, the majority of the increase related to the first full period of costs following the build out of the US teams supporting our California contract alongside significant promotion and marketing costs in support of raising user awareness and engagement including hard to reach communities. Finally, we saw increased costs as we strengthened our business development efforts in the US as indicated at the time of our equity fundraise in July 2023.
The total charge for share based payments in the period was £0.5m (2023 H1: £0.4m) with the rise reflecting a higher number of participants as we increased our headcount. Within administrative expenses, depreciation and amortisation increased to £2.6m (2023 H1 £1.5m) as capital expenditure increased for the US platform build following the California contract win.
Adjusted EBITDA for the full year is expected to be comfortably in line with market expectations, taking account of the fact that certain costs are skewed to the second half.
Taxation
The overall tax charge for the period was £1.1m (2023 H1: £1.2m credit) due predominantly to taxable profits accumulated in the US. This is partly offset by expected Research and Development expenditure credits in the UK. The prior period credit related to Research and Development expenditure credits and taxable losses.
Profit after tax
The Group profit after tax for the period was £3.9m (2023 H1: £0.5m loss). Basic earnings per share were 11p (2023 H1: 2p loss). Diluted earnings per share were 10p (2023 H1: 2p loss).
Balance Sheet
The strength of the Group's balance sheet with net assets of £25.3m (2023 H1: £10.6m), and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash inflow during the six months was £3.9m (2023 H1: £2.6m outflow). The focus on US platform investment gave rise to capital expenditure of £3.9m (2023 H1: £3.5m), offset by cash inflows from operating activities of £7.7m giving a net cash position at 30 June 2024 of £14.9m (2023 H1: £5.9m). The Group remains debt free and maintains an undrawn $9.5m working capital credit facility.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group’s intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2024 (2023: £nil) but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2024
| Note | Six months ended 30 June 2024 Unaudited | Six months ended 30 June 2023 Unaudited | Year ended 31 December 2023 Audited | |
| £'000 | £'000 | £'000 | ||
| Revenue | 8 | 32,494 | 11,660 | 33,337 |
| Cost of sales | 9 | (5,727) | (3,872) | (7,480) |
| Gross profit | 26,767 | 7,788 | 25,857 | |
| Administrative expenses | 9 | (22,078) | (9,606) | (28,119) |
| Operating Profit/(Loss) | 4,689 | (1,818) | (2,262) | |
| Analysed as: | ||||
| Adjusted EBITDA | 7,841 | 9 | 2,257 | |
| Depreciation & amortisation | 12 | (2,607) | (1,451) | (3,775) |
| Share based payment expense | (545) | (376) | (744) | |
| Operating Profit/(Loss) | 4,689 | (1,818) | (2,262) | |
| Interest income | 301 | 91 | 298 | |
| Profit/(Loss) before tax | 4,990 | (1,727) | (1,964) | |
| Tax | 10 | (1,070) | 1,202 | 1,795 |
| Profit/(Loss) after tax | 3,920 | (525) | (169) | |
| Other comprehensive income/(expense) | ||||
| Items that are or may be reclassified subsequently to profit or loss: | ||||
| Foreign currency translation differences | 72 | - | (161) | |
| Total comprehensive Profit/(loss) for the period | 3,992 | (525) | (330) | |
| Profit/(Loss) per share – basic (£) | 11 | 0.11 | (0.02) | (0.00) |
| Profit/(Loss) per share - diluted (£) | 11 | 0.10 | (0.02) | (0.00) |
Condensed Consolidated Balance Sheet
As at 30 June 2024
| Note | 30 June 2024 Unaudited | 30 June 2023 Unaudited | 31 December 2023 Audited | |
| £'000 | £'000 | £'000 | ||
| Assets | ||||
| Non-current assets | ||||
| Goodwill | 511 | 511 | 511 | |
| Development costs | 12 | 10,179 | 5,794 | 8,750 |
| Right of use asset | 31 | 53 | 42 | |
| Property, plant and equipment | 302 | 150 | 304 | |
| Deferred tax asset | 1,537 | 1,626 | 2,649 | |
| Total non-current assets | 12,560 | 8,134 | 12,256 | |
| Current assets | ||||
| Trade and other receivables | 13 | 6,234 | 2,355 | 7,174 |
| Contract assets | 2,157 | 180 | 251 | |
| Cash and cash equivalents | 14,940 | 5,850 | 11,004 | |
| Total current assets | 23,331 | 8,385 | 18,429 | |
| Total assets | 35,891 | 16,519 | 30,685 | |
| Liabilities | ||||
| Current liabilities | ||||
| Trade payables | (1,001) | (1,047) | (1,555) | |
| Contract liabilities | (5,738) | (3,096) | (5,156) | |
| Lease liability | (34) | (54) | (44) | |
| Accruals and other creditors | (3,551) | (913) | (2,521) | |
| Tax liabilities | (312) | (769) | (651) | |
| Total current liabilities | (10,636) | (5,879) | (9,927) | |
| Net current assets | 12,694 | 2,506 | 8,502 | |
| Net assets | 25,255 | 10,640 | 20,758 | |
| Equity | ||||
| Share capital | 1,831 | 1,653 | 1,825 | |
| Share premium account | 23,444 | 14,229 | 23,444 | |
| Retained earnings | 1,627 | (3,120) | (2,503) | |
| Share-based payment reserve | 2,431 | 1,867 | 2,142 | |
| Capital redemption reserve | 115 | 115 | 115 | |
| Merger reserve | (4,104) | (4,104) | (4,104) | |
| Translation reserve | (89) | - | (161) | |
| Total equity | 25,255 | 10,640 | 20,758 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2024
| Share capital | Share premium | Share Based Payment reserve | Retained earnings | Capital Redemption reserve | Merger reserve | Translation reserve | Total equity | |
| Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | - | 10,519 |
| Share based payments | - | - | 646 | - | - | - | - | 646 |
| Comprehensive income for the period | - | - | - | (525) | - | - | - | (525) |
| As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | - | 10,640 |
| Balance at 1 July 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | - | 10,640 |
| Comprehensive income for the period | - | - | - | 356 | - | - | - | 356 |
| Other comprehensive income | - | - | - | - | - | - | (161) | (161) |
| Total comprehensive income | 1,653 | 14,229 | 1,867 | (2,764) | 115 | (4,104) | (161) | 10,835 |
| Transactions with owners: | ||||||||
| Share options exercised | 7 | - | (261) | 261 | - | - | - | 7 |
| Share based payments | - | - | 120 | - | - | - | - | 120 |
| Shares issued | 165 | 9,215 | - | - | - | - | - | 9,380 |
| Deferred tax | - | - | 416 | - | - | - | - | 416 |
| As at 31 December 2023 | 1,825 | 23,444 | 2,142 | (2,503) | 115 | (4,104) | (161) | 20,758 |
| Balance at 1 January 2024 | 1,825 | 23,444 | 2,142 | (2,503) | 115 | (4,104) | (161) | 20,758 |
| Comprehensive income for the period | - | - | - | 3,920 | - | - | - | 3,920 |
| Other comprehensive income | - | - | - | - | - | - | 72 | 72 |
| Total comprehensive income | 1,825 | 23,444 | 2,142 | 1,417 | 115 | (4,104) | (89) | 24,750 |
| Transactions with owners: | ||||||||
| Share options exercised | 6 | - | (210) | 210 | - | - | - | 6 |
| Share based payments | - | - | 499 | - | - | - | - | 499 |
| As at 30 June 2024 | 1,831 | 23,444 | 2,431 | 1,627 | 115 | (4,104) | (89) | 25,255 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2024
| Six months ended 30 June 2024 Unaudited | Six months ended 30 June 2023 Unaudited | Year ended 31 December 2023 Audited | ||
| £'000 | £'000 | £'000 | ||
| Cash flows from operating activities | ||||
| Profit/(Loss) for the period | 3,920 | (525) | (169) | |
| Adjusted for: | ||||
| Depreciation & amortisation | 2,607 | 1,451 | 3,775 | |
| Income tax (paid)/received | (456) | 569 | 569 | |
| Share based payment expense | 545 | 376 | 744 | |
| Tax expense/(income) recognised | 1,070 | (1,202) | (1,795) | |
| Interest income | (301) | (91) | (298) | |
| Movements in working capital: | ||||
| (Increase)/decrease in trade and other receivables | (966) | 651 | (4,158) | |
| Increase / (decrease) in trade and other payables | 1,240 | (384) | 3,199 | |
| Net cashflow from operating activities | 7,659 | 845 | 1,867 | |
| Cash flows from investing activities | ||||
| Purchase of property, plant and equipment | (77) | (70) | (291) | |
| Additions to intangible assets | (3,947) | (3,508) | (8,713) | |
| Interest income | 301 | 91 | 298 | |
| Net cash used in investing activities | (3,723) | (3,487) | (8,706) | |
| Cash flows from financing activities | ||||
| Proceeds from issue of share capital | - | - | 9,923 | |
| Costs incurred from the issue of share capital | - | - | (536) | |
| Net cash from financing activities | - | - | 9,387 | |
| Net increase / (decrease) in cash and cash equivalents | 3,936 | (2,642) | 2,548 | |
| Exchange adjustments | - | - | (36) | |
| Cash and cash equivalents at the beginning of the period | 11,004 | 8,492 | 8,492 | |
| Cash and cash equivalents at the end of the period | 14,940 | 5,850 | 11,004 |
Latest Investor News
